Spots Global Cancer Trial Database for recurrent fallopian tube cancer
Every month we try and update this database with for recurrent fallopian tube cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT02122185 | Brenner Tumor Malignant Ascit... Malignant Pleur... Ovarian Clear C... Ovarian Endomet... Ovarian Mixed E... Ovarian Serous ... Ovarian Undiffe... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Ovaria... Stage IV Primar... | metformin hydro... placebo Chemotherapy | 18 Years - | University of Chicago | |
| Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer | NCT00278343 | Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | cediranib malea... laboratory biom... | 19 Years - | National Cancer Institute (NCI) | |
| Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01853644 | Recurrent Epith... Recurrent Fallo... Recurrent Prima... | Tivozanib | 18 Years - 110 Years | Northwestern University | |
| Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT02050009 | Ovarian Papilla... Ovarian Serous ... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... | metformin hydro... carboplatin paclitaxel laboratory biom... | 18 Years - | Fox Chase Cancer Center | |
| Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT01962948 | Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | paclitaxel ganetespib laboratory biom... | 18 Years - | Fox Chase Cancer Center | |
| Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | NCT01100372 | Fallopian Tube ... Ovarian Cancer Primary Periton... | gemcitabine hyd... liposome-encaps... quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009) | NCT00562640 | Fallopian Tube ... Ovarian Cancer Primary Periton... | filgrastim therapeutic aut... cyclophosphamid... laboratory biom... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | NCT00872989 | Fallopian Tube ... Ovarian Cancer Primary Periton... | docetaxel vandetanib | 18 Years - 120 Years | SWOG Cancer Research Network | |
| SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin | NCT01200797 | Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | SJG-136 laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen | NCT00305838 | Fallopian Tube ... Ovarian Cancer Primary Periton... | tamoxifen citra... diagnostic labo... | - | National Cancer Institute (NCI) | |
| Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer | NCT01764789 | Anxiety Disorde... Depression Fatigue Leydig Cell Tum... Ovarian Sarcoma Ovarian Stromal... Pain Peritoneal Carc... Pseudomyxoma Pe... Recurrent Breas... Recurrent Cervi... Recurrent Endom... Recurrent Fallo... Recurrent Gesta... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Recurrent Vagin... Recurrent Vulva... | questionnaire a... quality-of-life... psychosocial as... behavioral inte... cognitive inter... educational int... | 21 Years - 85 Years | Ohio State University Comprehensive Cancer Center | |
| Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01853644 | Recurrent Epith... Recurrent Fallo... Recurrent Prima... | Tivozanib | 18 Years - 110 Years | Northwestern University | |
| Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | NCT00617773 | Fallopian Tube ... Ovarian Cancer Primary Periton... | hu3S193 | 18 Years - | Recepta Biopharma | |
| A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. | NCT05335993 | Recurrent Ovari... Recurrent Epith... Recurrent Epith... Recurrent Fallo... Peritoneal Canc... Recurrent Carci... Adenocarcinoma ... | Oregovomab Niraparib | 18 Years - 99 Years | CanariaBio Inc. | |
| Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT01747798 | Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | auranofin laboratory biom... | 18 Years - | Mayo Clinic | |
| Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma | NCT00504257 | Fallopian Tube ... Ovarian Cancer Malignant Tumor... | Avastin Docetaxel | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | NCT00388037 | Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... | sunitinib malat... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | NCT01673217 | Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | decitabine NY-ESO-1 peptid... pegylated lipos... sargramostim incomplete Freu... immunohistochem... liquid chromato... mass spectromet... reverse transcr... laboratory biom... DNA methylation... enzyme-linked i... | 18 Years - | Roswell Park Cancer Institute | |
| Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | NCT00617773 | Fallopian Tube ... Ovarian Cancer Primary Periton... | hu3S193 | 18 Years - | Recepta Biopharma | |
| Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers | NCT03564340 | Recurrent Ovari... Recurrent Fallo... Recurrent Prima... Recurrent Endom... | REGN4018 cemiplimab Sarilumab | 18 Years - | Regeneron Pharmaceuticals | |
| Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi | NCT05126342 | Recurrent Ovari... Recurrent Fallo... Primary Periton... | Niraparib Dostarlimab | 18 Years - | AGO Research GmbH | |
| Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | NCT01673217 | Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | decitabine NY-ESO-1 peptid... pegylated lipos... sargramostim incomplete Freu... immunohistochem... liquid chromato... mass spectromet... reverse transcr... laboratory biom... DNA methylation... enzyme-linked i... | 18 Years - | Roswell Park Cancer Institute | |
| A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. | NCT05335993 | Recurrent Ovari... Recurrent Epith... Recurrent Epith... Recurrent Fallo... Peritoneal Canc... Recurrent Carci... Adenocarcinoma ... | Oregovomab Niraparib | 18 Years - 99 Years | CanariaBio Inc. | |
| VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01666444 | Epithelial Ovar... Fallopian Tube ... Primary Periton... | pegylated lipos... VTX-2337 Placebo | 18 Years - | Celgene | |
| CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen | NCT00305838 | Fallopian Tube ... Ovarian Cancer Primary Periton... | tamoxifen citra... diagnostic labo... | - | National Cancer Institute (NCI) | |
| CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen | NCT00305838 | Fallopian Tube ... Ovarian Cancer Primary Periton... | tamoxifen citra... diagnostic labo... | - | National Cancer Institute (NCI) | |
| Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers | NCT03564340 | Recurrent Ovari... Recurrent Fallo... Recurrent Prima... Recurrent Endom... | REGN4018 cemiplimab Sarilumab | 18 Years - | Regeneron Pharmaceuticals | |
| Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer | NCT00278343 | Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | cediranib malea... laboratory biom... | 19 Years - | National Cancer Institute (NCI) | |
| Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer | NCT01764789 | Anxiety Disorde... Depression Fatigue Leydig Cell Tum... Ovarian Sarcoma Ovarian Stromal... Pain Peritoneal Carc... Pseudomyxoma Pe... Recurrent Breas... Recurrent Cervi... Recurrent Endom... Recurrent Fallo... Recurrent Gesta... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Recurrent Vagin... Recurrent Vulva... | questionnaire a... quality-of-life... psychosocial as... behavioral inte... cognitive inter... educational int... | 21 Years - 85 Years | Ohio State University Comprehensive Cancer Center | |
| Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | NCT00303888 | Fallopian Tube ... Ovarian Cancer Primary Periton... | docetaxel idronoxil placebo | 18 Years - 120 Years | Yale University | |
| Laboratory Study in Predicting Tumor Response to Chemotherapy in Patients With Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | NCT00897039 | Fallopian Tube ... Ovarian Cancer Primary Periton... | flow cytometry immunohistochem... | - | National Cancer Institute (NCI) | |
| Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | NCT01100372 | Fallopian Tube ... Ovarian Cancer Primary Periton... | gemcitabine hyd... liposome-encaps... quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009) | NCT00562640 | Fallopian Tube ... Ovarian Cancer Primary Periton... | filgrastim therapeutic aut... cyclophosphamid... laboratory biom... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer | NCT01105650 | Ovarian Cancer Fallopian Tube ... Primary Periton... Breast Cancer | Fludarabine Cyclophosphamid... Cyclosporine Natural killer ... IL-2 Methylprednisol... Methylprednisol... Interleukin-2 | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01853644 | Recurrent Epith... Recurrent Fallo... Recurrent Prima... | Tivozanib | 18 Years - 110 Years | Northwestern University | |
| S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | NCT00872989 | Fallopian Tube ... Ovarian Cancer Primary Periton... | docetaxel vandetanib | 18 Years - 120 Years | SWOG Cancer Research Network | |
| WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian Cancer | NCT01144442 | Ovarian Cancer Fallopian Tube ... Peritoneal Carc... | Hyperthermic in... Isotonic saline... Surgery Carboplatin Paclitaxel | 16 Years - 90 Years | Masonic Cancer Center, University of Minnesota | |
| Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer | NCT01105650 | Ovarian Cancer Fallopian Tube ... Primary Periton... Breast Cancer | Fludarabine Cyclophosphamid... Cyclosporine Natural killer ... IL-2 Methylprednisol... Methylprednisol... Interleukin-2 | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | NCT00045461 | Fallopian Tube ... Ovarian Cancer Primary Periton... | carboplatin ifosfamide hyperthermia tr... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01666444 | Epithelial Ovar... Fallopian Tube ... Primary Periton... | pegylated lipos... VTX-2337 Placebo | 18 Years - | Celgene | |
| Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer | NCT01652794 | Leydig Cell Tum... Ovarian Sarcoma Ovarian Stromal... Pseudomyxoma Pe... Recurrent Cervi... Recurrent Endom... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Recurrent Vagin... Recurrent Vulva... | stereotactic bo... carboplatin gemcitabine hyd... laboratory biom... pharmacogenomic... | 19 Years - | Case Comprehensive Cancer Center | |
| Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | NCT01402271 | Fallopian Tube ... Ovarian Cancer Primary Periton... | carboplatin paclitaxel pazopanib hydro... laboratory biom... pharmacological... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
